Put companies on watchlist
RHÖN-KLINIKUM Aktiengesellschaft
ISIN: DE0007042301
WKN: 704230
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

RHÖN-KLINIKUM Aktiengesellschaft · ISIN: DE0007042301 · EQS - Company News (35 News)
Country: Germany · Primary market: Germany · EQS NID: 1248202
11 November 2021 08:00AM

RHÖN-KLINIKUM Aktiengesellschaft: RHÖN-KLINIKUM AG closes first nine months of 2021 with increase in revenues


DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Quarter Results/Quarter Results
RHÖN-KLINIKUM Aktiengesellschaft: RHÖN-KLINIKUM AG closes first nine months of 2021 with increase in revenues

11.11.2021 / 08:00
The issuer is solely responsible for the content of this announcement.


Corporate News

Bad Neustadt a. d. Saale | 11 November 2021

 

RHÖN-KLINIKUM AG closes first nine months of 2021 with increase in revenues

In the first nine months of financial year 2021, the Group of RHÖN-KLINIKUM AG recorded revenues of € 1,030.6 million after € 1,018.7 million in the same period of the previous year, an increase of 1.2%. At 71.1 million euros, earnings before interest, taxes, depreciation and amortisation (EBITDA) were up by 10.3 million euros compared with the same level of the previous year (€ 60.8 million). The EBITDA margin was 6.9%. Taking account of depreciation/amortisation, financing costs and taxes, EBITDA resulted in a consolidated profit of + € 15.5 million after + € 2.3 million in the previous year. From January to September we treated 632,883 patients, 4.2% more than in the same period last year (previous year, Q3 2020: 607,151).

Over the past months, RHÖN-KLINIKUM AG's efforts to cope with the COVID-19 pandemic have continued undiminished. Dr. Christian Höftberger, Chairman of the Board of Management of RHÖN-KLINIKUM AG, said: "We are currently witnessing an exponential rise in infections. Combined with seasonal spikes in diseases, this is exacerbating the current situation in hospitals. Yet, unlike at the beginning of the pandemic we now benefit from our extensive experience in treating COVID-19 patients and are hoping to see manageable courses of the disease thanks to the Corona vaccinations. But for all our optimism we also note that the selfless, outstanding commitment of our employees over a period of now one and a half years - similar to the trend seen nationally - is taking its toll in terms of increasingly exhausted medical staff."

Taking on challenges together - appeal to federal politicians

The most pressing tasks of RHÖN-KLINIKUM AG also include the following three areas of action: strengthening nursing and medical care, ensuring that hospitals concentrate on their core activities, and pooling special know-how. The Company is tackling these areas with the involvement of all employees whilst being helped by its collaboration with the companies of the Asklepios Kliniken GmbH & Co. KGaA group.

RHÖN-KLINIKUM AG sees a need for reform in healthcare policy. The Company wholly welcomes the wish of the exploratory coalition partners SPD, Bündnis 90/Die Grünen and FDP to make preparedness and prevention a guiding principle of German healthcare policy. The basic idea of more cross-sector cooperation is also a sensible one, but should be accompanied by a radical reduction in sectoral boundaries - particularly between outpatient and inpatient care - as it is worked out in detail.

"Currently what we really need is solution-based approaches to reduce the significant investment backlog in the German healthcare industry, and we appeal to the exploratory coalition partners to explicitly address this issue", said Höftberger. Also badly needed is significantly more investment in building infrastructure and medical technology. In future, violations of the principle of dual financing must no longer be condoned. Instead, effective sanction mechanisms must be put in place.

Guidance

Thanks to the positive business performance in the first nine months of financial year 2021, the Board of Management of RHÖN‐KLINIKUM AG on 8 October 2021 decided to adjust the previous forecast for earnings before interest, tax and depreciation/amortisation (EBITDA) for financial year 2021 (put at between € 72.5 million and € 82.5 million). For financial year 2021 the Board of Management of the Company now expects an EBITDA of between € 92 million and € 102 million. The forecast for revenues for financial year 2021 of € 1.4 billion within a range of +/‐ 5% is maintained. This forecast reflects the heightened regulatory interference by the German legislator, such as the Regulation on Nursing Staff Floors (Pflegepersonaluntergrenzenverordnung, PpUGV) and the Nursing Staff Strengthening Act (Pflegepersonalstärkungsgesetz, PpSG). We also note considerable uncertainties in the forecast in terms of the further course of the COVID-19 pandemic and any regulatory measures impacting our remuneration structure in 2021.

Full results are published in the Quarterly Statement at:
https://en.rhoen-klinikum-ag.com/investor-relations/publications/interim-reports-quarterly-statements.html

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 809,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs around 18,450 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com

Contact:

RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury
Julian Schmitt | T. +49 9771 65-12250 | julian.schmitt@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale



11.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 1248202

 
End of News DGAP News Service

1248202  11.11.2021 

fncls.ssp?fn=show_t_gif&application_id=1248202&application_name=news&site_id=boersengefluester_html
Visual performance / price development - RHÖN-KLINIKUM Aktiengesellschaft
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.